Patents by Inventor Arnab DE

Arnab DE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210324052
    Abstract: The present invention relates to stable formulations comprising antibodies or antigen-binding fragments thereof that bind to respiratory syncytial virus (RSV). Also provided are methods of preventing and/or treating RSV-related diseases with the formulations of the invention.
    Type: Application
    Filed: October 14, 2019
    Publication date: October 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Venus Hashemi, Arnab De, Chakravarthy Nachu Narasimhan
  • Publication number: 20210236640
    Abstract: Provided is a method of determining the stability increase provided by a non-reducing sugar in a pharmaceutical composition containing a protein therapeutic, the method comprising: (i) providing: a first pharmaceutical composition comprising an aqueous solution of the protein therapeutic in the substantial absence of a non-reducing sugar, wherein the first pharmaceutical composition has a first B22 value and a second pharmaceutical composition comprising an aqueous solution of the protein therapeutic and the non-reducing sugar, wherein the second pharmaceutical composition has a second B22 value; (ii) determining the difference between the first and second B22 values; and (iii) predicting the stability increase provided by the non-reducing sugar based on the difference in B22 values.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 5, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Arnab De, Chakravarthy Nachu Narasimhan
  • Publication number: 20200354453
    Abstract: The present invention relates to stable formulations of antibodies against T cell immunoreceptor with Ig and ITIM domains (TIGIT), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
    Type: Application
    Filed: May 1, 2018
    Publication date: November 12, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Arnab De, Chakravarthy Nachu Narasimhan
  • Publication number: 20200262922
    Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Soumendu Bhattacharya, Chakravarthy Nachu Narasimhan, Manoj K. Sharma, Xiaoyu Yang, Arnab De, Rubi Burlage, Jason K. Cheung
  • Patent number: 10216501
    Abstract: Described are methods, systems and computer-readable media storing instructions that when executed on one or more processors execute a process for generating second program code in a statically typed programming language from first program code in a dynamically typed programming language. The first program code contains or, when executed, generates or operates on a dynamically typed array. The second program code may be generated by classifying the dynamically typed array into one of multiple categories, such as homogeneous, heterogeneous, or another, based on the array contents, array usage, and/or user input, and generating the second program code in the statically typed programming language based on the classification(s).
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 26, 2019
    Assignee: The MathWorks, Inc.
    Inventors: Arnab De, Frederick M. Smith, Denis Gurchenkov
  • Patent number: 10146511
    Abstract: System and method for estimating package implementation effort of software development life cycle (SDLC) activities are disclosed. In an embodiment, information associated with a plurality of configuration parameters of a SDLC activity is obtained. The configuration parameters include an organization, an industry vertical, business criticality of functionalities within the industry vertical, influencing factors and a utilization factor. Further, one or more of configuration factors associated with the SDLC activity are determined based on the information associated with the configuration parameters. Furthermore, functional effort for configuration of the SDLC activity is estimated based on the configuration factors. In addition, information associated with a plurality of customization parameters of the SDLC activity is obtained. Moreover, customization effort for customization of the SDLC activity is estimated based on the information associated with the customization parameters.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 4, 2018
    Assignee: Tata Consultancy Services Limited
    Inventors: Rajib Banerjee, Suranjan Chatterjee, Arnab De
  • Publication number: 20170153873
    Abstract: System and method for estimating package implementation effort of software development life cycle (SDLC) activities are disclosed. In an embodiment, information associated with a plurality of configuration parameters of a SDLC activity is obtained. The configuration parameters include an organization, an industry vertical, business criticality of functionalities within the industry vertical, influencing factors and a utilization factor. Further, one or more of configuration factors associated with the SDLC activity are determined based on the information associated with the configuration parameters. Furthermore, functional effort for configuration of the SDLC activity is estimated based on the configuration factors. In addition, information associated with a plurality of customization parameters of the SDLC activity is obtained.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 1, 2017
    Applicant: Tata Consultancy Services Limited
    Inventors: Rajib BANERJEE, Suranjan CHATTERJEE, Arnab DE
  • Publication number: 20160357533
    Abstract: Described are methods, systems and computer-readable media storing instructions that when executed on one or more processors execute a process for generating second program code in a statically typed programming language from first program code in a dynamically typed programming language. The first program code contains or, when executed, generates or operates on a dynamically typed array. The second program code may be generated by classifying the dynamically typed array into one of multiple categories, such as homogeneous, heterogeneous, or another, based on the array contents, array usage, and/or user input, and generating the second program code in the statically typed programming language based on the classification(s).
    Type: Application
    Filed: May 31, 2016
    Publication date: December 8, 2016
    Applicant: The MathWorks, Inc.
    Inventors: Arnab De, Frederick M. Smith, Denis Gurchenkov
  • Patent number: 9089539
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 28, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Arnab De
  • Publication number: 20140212419
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: February 18, 2014
    Publication date: July 31, 2014
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMARCHI, Arnab DE
  • Patent number: 8697838
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: April 15, 2014
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, Arnab De
  • Publication number: 20110065633
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: January 21, 2009
    Publication date: March 17, 2011
    Inventors: Richard D. Dimarchi, Arnab De
  • Publication number: 20100331246
    Abstract: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and more typically greater than 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Application
    Filed: July 28, 2010
    Publication date: December 30, 2010
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Richard DIMARCHI, Arnab DE